Previous 10 | Next 10 |
2023-08-16 07:10:46 ET Kamada press release ( NASDAQ: KMDA ): Q2 GAAP EPS of $0.04 beats by $0.02 . Revenue of $37.4M (+58.5% Y/Y) beats by $3.23M . Adjusted EBITDA, as detailed in the tables below, was $6.0 million in the second quarter of 2023, as compared to...
Second Quarter 2023 Revenues were $37.4 Million, Representing a 59% Increase Year-over-Year; First Half 2023 Revenues of $68.2 Million, Up 32% Year-over-Year First Half 2023 Adjusted EBITDA of $9.9 Million, Up 24% Year-over-Year Robust Second Quarter Results and ...
2023-08-15 12:15:53 ET Kamada ( NASDAQ: KMDA ) is scheduled to announce Q2 earnings results on Wednesday, August 16th, before market open. The consensus EPS Estimate is $0.03 and the consensus Revenue Estimate is $34.17M (+44.8% Y/Y). Over the last 2 years, KMDA has ...
REHOVOT, Israel and HOBOKEN, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today...
The Extended Agreement Term is Until March 2026 The Company Generated Approximately $16 Million in Revenue from Sales of KEDRAB to Kedrion in 2022 and A nticipates a Significant I ncrease in 2023 REHOVOT, Israel, and HOBOKEN, N.J., July 12, 2023 (...
2023-06-21 05:10:17 ET Summary Kamada Ltd. has potential catalysts for growth, capital attraction and regulatory tailwinds. The company's valuation appears attractive, with forward estimates suggesting a possible re-rating. Key risks center around the investment in 2x new manu...
2023-05-24 12:10:27 ET Kamada ( NASDAQ: KMDA ) stock rose ~12% on Wednesday after the company said a major shareholder and private equity firm FIMI Opportunity Funds will buy $60M worth of its ordinary shares in a private placement. Under the agreement, Kamada will issue ~...
Shares of Kamada Ltd. (NASDAQ: KMDA) traded at a new 52-week high today and are currently trading at $5.29. So far today, approximately 287.54k shares have been exchanged, as compared to an average 30-day volume of 20,106 shares. Kamada Ltd. develops, produces, and markets plasma-derived prot...
2023-05-24 10:07:34 ET Gainers: Enveric Biosciences ( ENVB ) +100% . Zura Bio ( ZURA ) +37% . Kamada ( KMDA ) +19% . Organogenesis ( ORGO ) +16% . OptimizeRx ( OPRX ) +14% . Losers: PTC Therapeutics ( PTCT ) -24% ....
2023-05-24 07:14:34 ET Kamada press release ( NASDAQ: KMDA ): Q1 Non-GAAP EPS of $0.04 in-line. Revenue of $30.7M (+9.3% Y/Y) misses by $3.46M . For further details see: Kamada Non-GAAP EPS of $0.04 in-line, revenue of $30.7M misses by $3.46M
News, Short Squeeze, Breakout and More Instantly...
2024-07-17 17:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-17 04:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...